How to buy Silverback Therapeutics (SBTX.US) stock | finder.com

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Silverback Therapeutics stock

Own Silverback Therapeutics stock in just a few minutes.

Silverback Therapeutics, Inc is a biotechnology business based in the US. Silverback Therapeutics shares (SBTX) are listed on the NASDAQ and all prices are listed in US Dollars. Silverback Therapeutics employs 54 staff and has a market cap (total outstanding shares value) of USD$1.3 billion.

How to buy shares in Silverback Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Silverback Therapeutics. Find the stock by name or ticker symbol: SBTX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Silverback Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Silverback Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Silverback Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Silverback Therapeutics share price

Use our graph to track the performance of SBTX stocks over time.

Silverback Therapeutics shares at a glance

Information last updated 2021-04-09.
52-week rangeUSD$21 - USD$63.41
50-day moving average USD$48.7451
200-day moving average USD$43.8369
Wall St. target priceUSD$52.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Silverback Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Silverback Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Silverback Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -10.03%
Return on equity TTM -17.47%
Profit margin 0%
Book value N/A
Market capitalisation USD$1.3 billion

TTM: trailing 12 months

Shorting Silverback Therapeutics shares

There are currently 2.5 million Silverback Therapeutics shares held short by investors – that's known as Silverback Therapeutics's "short interest". This figure is 14.9% up from 2.2 million last month.

There are a few different ways that this level of interest in shorting Silverback Therapeutics shares can be evaluated.

Silverback Therapeutics's "short interest ratio" (SIR)

Silverback Therapeutics's "short interest ratio" (SIR) is the quantity of Silverback Therapeutics shares currently shorted divided by the average quantity of Silverback Therapeutics shares traded daily (recently around 200922.12389381). Silverback Therapeutics's SIR currently stands at 12.43. In other words for every 100,000 Silverback Therapeutics shares traded daily on the market, roughly 12430 shares are currently held short.

To gain some more context, you can compare Silverback Therapeutics's short interest ratio against those of similar companies.

However Silverback Therapeutics's short interest can also be evaluated against the total number of Silverback Therapeutics shares, or, against the total number of tradable Silverback Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Silverback Therapeutics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Silverback Therapeutics shares in existence, roughly 70 shares are currently held short) or 0.115% of the tradable shares (for every 100,000 tradable Silverback Therapeutics shares, roughly 115 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Silverback Therapeutics.

Find out more about how you can short Silverback Therapeutics stock.

Silverback Therapeutics share dividends

We're not expecting Silverback Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

Silverback Therapeutics overview

Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site